Afatinib: A first-line treatment for selected patients with metastatic non-small-cell lung cancer

American Journal of Health-System Pharmacy

Volumn 71, Issue 22, 2014, Pages 1933-1938

  Engle, Jeff A ^a   Kolesar, Jill M ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFATINIB; CISPLATIN; ERLOTINIB; GEFITINIB; GEMCITABINE; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE;

ACNE; AREA UNDER THE CURVE; DERMATITIS; DIARRHEA; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; EPIDERMAL GROWTH FACTOR RECEPTOR GENE; GENE; GENE MUTATION; HUMAN; MAXIMUM PLASMA CONCENTRATION; METASTASIS; NON SMALL CELL LUNG CANCER; PARONYCHIA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RASH; REVIEW; STOMATITIS; ANTAGONISTS AND INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; DRUG RESISTANCE; GENETICS; LUNG NEOPLASMS; MUTATION; PATHOLOGY;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; DRUG RESISTANCE, NEOPLASM; HUMANS; LUNG NEOPLASMS; MUTATION; NEOPLASM METASTASIS; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84911367943     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp130654     Document Type: Review

References (22)

1. National Cancer Institute. What you need to know about lung cancer: types of lung cancer. www.cancer.gov/cancertopics/wyntk/lung/page4 (accessed 2014 Jun 6).
2. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics 2014. CA Cancer J Clin. 2014; 64:9-29.
3. Azzoli CG, Temin S, Aliff T et al. 2011 focused update of 2009 American Society of Clinical Oncology clinical practice guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol. 2011; 29:3825-31.
4. National Comprehensive Cancer Network. NCCN practice guidelines version 2.2013: non-small cell lung cancer. www.nccn.org/professionals/physician-gls/pdf/nscl.pdf (accessed 2013 Jul 2).
5. Chih-Hsin Yang J, Shih JY, Su WC et al. Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase II trial. Lancet Oncol. 2012; 13:539-48.
6. Gilotrif (afatinib) prescribing information. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.; 2013.
7. Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer. 2005; 5:341-54.
8. Gazdar AD. Epidermal growth factor receptor inhibition in lung cancer: the evolving role of individualized therapy. Cancer Metastasis Rev. 2010; 29:37-48.
9. Soria JC, Mok TS, Cappuzzo F, Janne PA. EGFR-mutated oncogene-addicted nonsmall cell lung cancer: current trends and future prospects. Cancer Treat Rev. 2012; 38:416-30.
10. Solca F, Dahl G, Zoephel A et al. Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker. J Pharmacol Exp Ther. 2012; 343:342-50.
11. Li D, Ambrogio L, Shimamura T et al. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene. 2008; 27:4702-11.
12. Spicer JF, Rudman SM. EGFR inhibitors in non-small cell lung cancer (NSCLC): the emerging role of the dual irreversible EGFR/HER2 inhibitor BIBW 2992. Target Oncol. 2010; 5:245-55.
13. Stopfer P, Marzin K, Narjes H et al. Afatinib pharmacokinetics and metabolism after oral administration to healthy male volunteers. Cancer Chemother Pharmacol. 2012; 69:1051-61.
14. Yap TA, Vidal L, Adam J et al. Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors. J Clin Oncol. 2010; 28:3965-72.
15. Murakami H, Tamura T, Takahashi T et al. Phase I study of continuous afatinib (BIBW 2992) in patients with advanced non-small cell lung cancer after prior chemotherapy/erlotinib/gefitinib (LUX-Lung 4). Cancer Chemother Pharmacol. 2012; 69:891-9.
16. Miller VA, Hirsh V, Cadranel J et al. Afatinib versus placebo for patients with advanced, metastatic non-small cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. Lancet Oncol. 2012; 13:528-38.
17. Yang JC, Shih JY, Su WC et al. Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial. Lancet Oncol. 2012; 13:539-48.
18. Katakami N, Atagi S, Goto K et al. LUX-Lung 4: a phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both. J Clin Oncol. 2013; 31:3335-41.
19. Sequist LV, Yang JC, Yamamoto N et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013; 31:3327-34.
20. Yang JC, Hirsh V, Schuler M et al. Symptom control and quality of life in LUXLung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013; 31:3342-50.
21. Wu YL, Zhou C, Hu CP et al. LUX-Lung 6: a randomized, open-label, phase III study of afatinib versus gemcitabine/cisplatin as first-line treatment for Asian patients with EGFR mutation-positive advanced adenocarcinoma of the lung. Abstract presented at ASCO Annual Meeting. Chicago, IL; 2013 Jun.
22. Gordon MS, Mendelson DS, Gross M et al. A phase I, open-label, dose-escalation study of continuous once-daily oral treatment with afatinib in patients with advanced solid tumors. Invest New Drugs. 2013; 31:409-16.